Clinical Trial

NLS Pharmaceutics Announces Selection of Strategic Partner and Securing a Bridge Loan

NLS has executed a non-binding term sheet for licensing of NLS intellectual propertyNLS has secured an additional bridge loan through…

12 months ago

PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update

TARRYTOWN, NY / ACCESSWIRE / November 15, 2023 / PaxMedica, Inc. (NASDAQ:PXMD), a biopharmaceutical company focused on advancing treatments for…

12 months ago

Yunu Integration to Florence Improves Imaging Accuracy and Workflow Efficiency

Partnership extends capability for trial imaging integration to Florence Healthcare's 18,000 activated clinical trial sites.ATLANTA, GA / ACCESSWIRE / November…

12 months ago

FSD Pharma Files Supplement to Management Information Circular in Connection with Special Meeting to be Held on November 20, 2023

TORONTO, ON / ACCESSWIRE / November 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical…

12 months ago

CNS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Reiterates Company is on Track to Achieve Milestones for Berubicin Potentially Pivotal Study Before Year End

- Enrollment numbers rise to 239 in ongoing potentially pivotal study of Berubicin for treatment of GBM; Expected full enrollment…

12 months ago

NanoViricides Has Filed its Quarterly Report – NV-387 Broad-Spectrum Antiviral in Clinical Trials Has Additional Applications

SHELTON, CT / ACCESSWIRE / November 15, 2023 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), reports that it has filed…

12 months ago

PharmAla Biotech and Filament Health Announce Release of Second Batch of GMP MDMA Capsules

Filament Health and PharmAla Biotech also completed shipments to a number of Australian clientsVANCOUVER, British Columbia, Nov. 15, 2023 (GLOBE…

12 months ago

Carmot Therapeutics Commenced Phase 2 Clinical Trial of Novel Dual GLP-1/GIP Receptor Agonist CT-868 for the Treatment of Type 1 Diabetes

– Randomized, placebo-controlled trial to assess 16-week treatment with CT-868 in participants with overweight or obesity with type 1 diabetes…

12 months ago

Awakn Life Sciences Receives Regulatory and Ethical Approval for Phase III Clinical Trial of AWKN-P001

AWKN-P001 is a N-methyl-D-aspartate Receptor-Modulating Drug Used in Combination with Psycho-Social Support for the Treatment of Severe Alcohol Use DisorderToronto,…

12 months ago